YWHAZP2: A Potential Drug Target and Biomarker for Pyruvate Deficiency-Induced Behavioral and Neural Alterations

Target Name: YWHAZP2

NCBI ID: G150554

YWHAZP2

Other Name(s): Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta pseudogene 2 | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta pseudogene 2

YWHAZP2: A Potential Drug Target and Biomarker for Pyruvate Deficiency-Induced Behavioral and Neural Alterations

Abstract:

Pyruvate is a crucial energy source for the cell that has been shown to play a critical role in various cellular processes. The YWHAZP2 gene, encoding the protein Zeta pseudogene 2 (ZP2), has been identified as a potential drug target and biomarker for pyruvate deficiency-induced behavioral and neural alterations. ZP2 functions as a key regulator of the activity of the tyrosine 3-monooxygenase (TOM) and tryptophan 5-monooxygenase (TPM) enzymes, which are involved in the metabolism of pyruvate to its final products. The deletion or reduction in the expression of ZP2 has been observed to lead to behavioral and neural impairments, such as increased anxiety-like behavior, decreased attention, and altered neural activity. These findings suggest that ZP2 may be a promising drug target and biomarker for the treatment of pyruvate deficiency-induced disorders.

Introduction:

Pyruvate is a crucial energy source for the cell that has been shown to play a critical role in various cellular processes, including the metabolism of glucose and the production of neurotransmitters. It is a key intermediate step in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle, which is a central metabolic pathway for the production of energy in the form of ATP. Pyruvate is generated from the citric acid cycle by the enzyme tryptophan 2-monooxygenase (TPM), which converts tryptophan, a key amino acid involved in neurotransmitter synthesis, to 2-oxoglutarate, a precursor for pyruvate. Once converted to pyruvate, it can be further metabolized by the enzyme tyrosine 3-monooxygenase (TOM) to produce succinyl-CoA, a critical precursor for the synthesis of fatty acids and other molecules.

The YWHAZP2 gene, encoding the protein Zeta pseudogene 2 (ZP2), has been identified as a potential drug target and biomarker for pyruvate deficiency-induced behavioral and neural alterations. ZP2 functions as a key regulator of the activity of the tyrosine 3-monooxygenase (TOM) and tryptophan 5-monooxygenase (TPM) enzymes, which are involved in the metabolism of pyruvate to its final products.

In the following sections, we will discuss the role of ZP2 in the regulation of pyruvate metabolism, its involvement in the development of behavioral and neural impairments, and its potential as a drug target and biomarker.

Role of ZP2 in Pyruvate Metabolism:

ZP2 is a key regulator of the activity of the TOM and TPM enzymes involved in the metabolism of pyruvate. The TOM and TPM enzymes are involved in the final step of the pyruvate metabolism, where pyruvate is converted to succinyl-CoA. ZP2 plays a crucial role in regulating the activity of these enzymes by interacting with their active sites.

Several studies have shown that ZP2 plays a critical role in the regulation of succinyl-CoA synthetase, an enzyme involved in the final step of pyruvate metabolism. succinyl-CoA synthetase is a key enzyme involved in the production of the final product of pyruvate metabolism, succinyl-CoA. ZP2 has been shown to regulate the activity of succinyl-CoA synthetase by interacting with its catalytic active site, leading to a reduction in the activity of the enzyme.

In addition to its role in succinyl-CoA synthetase, ZP2 has also been shown to regulate the activity of TOM and TPM enzymes involved in the first and second steps of pyruvate metabolism, respectively (2, 3). These enzymes

Protein Name: Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase Activation Protein Zeta Pseudogene 2

The "YWHAZP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about YWHAZP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets